REMAP CAP

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 (REMAP CAP COVID-19)

REMAP-CAP is a randomised, multi-factorial, adaptative platform trial for community-acquired pneumonia which was later adapted to the COVID-19 pandemics.

 

Primary objective: To identify the effect of a range of interventions to improve outcome as defined by 21-day ICU free days. 

 

Type of studyInterventionalRCT, Phase 3  

 

Treatment testedMultiple

 

Countries: Multiple

 

Sample sizeAdaptative trial therefore no prespecified sample size 

 

Study participants:  Suspected or proven COVID-19 infection (for the COVID-19 Domains)

 

Study statusOngoing

 

Study documents

 

Investigators (study chairs)

  • Steve Webb, ProfMonash University
  • Colin McArthur, DrMedical Research Institute of New Zealand
  • Marc Bonten, ProfUMC Utrecht
  • Lennie Derde, MDUMC Utrecht
  • Marshall Marshall, Prof Unity Health Toronto
  • Angus Derek, ProfUniversity of Pittsburgh Medical Center

 

More information

 

 

Last updated: September 2020

 

Disclaimer 
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.